Proposed Placing to raise approximately £5.5m

Creo Medical is raising cash, but profitability and product success remain distant and unproven.

What the company is saying

Creo Medical Group plc is telling investors that it is at a turning point, raising approximately £5.5 million through a share placing at 15 pence per share—a 31.9% premium to the last closing price—to fund its next phase of growth. The company highlights strong Q1 FY26 revenue growth of about 60% year-on-year, positioning this as evidence of commercial momentum and operational improvement. Management claims that the combined proceeds from the placing, a £2 million convertible loan note from Development Bank of Wales, and the anticipated sale of its remaining 49% stake in Creo Medical Europe will provide enough cash to reach sustainable cash flow and profitability. The announcement is careful to emphasize director participation in the placing (about £2.15 million), suggesting insider confidence, and it repeatedly frames the capital raise as a proactive move to support growth and mitigate risks around the asset sale. However, the company buries the fact that the agreement for the CME stake sale is non-binding and omits any detailed breakdown of how the new funds will be allocated. The tone is upbeat and confident, with management projecting belief in future success rather than providing hard evidence. Luis Collantes, CEO of Creo Medical Europe, is named as the counterparty in the potential asset sale, which could be significant if he brings operational continuity or strategic alignment, but the announcement does not clarify his broader influence or intentions. This narrative fits a classic growth-company IR strategy: highlight recent wins, frame capital raises as opportunity-driven, and downplay ongoing losses and execution risks. Compared to prior communications (where available), the messaging is more forward-leaning, with a heavier emphasis on future product launches and revenue potential.

What the data suggests

The disclosed numbers show a company with improving but still challenged fundamentals. Q1 FY26 revenue growth is approximately 60% year-on-year, which is at the upper end of management’s expectations and a genuine positive. Cash and cash equivalents increased from £8.7 million at 31 December 2024 to £12.4 million at 31 December 2025, likely boosted by the €30.4 million received from the earlier sale of a 51% stake in Creo Medical Europe. Comprehensive loss from continuing operations narrowed from £27.8 million in 2024 to £17.5 million in 2025, indicating progress but still a substantial annual loss. The company forecasts a 15% reduction in underlying operating costs for FY26, but does not provide a detailed cost breakdown or evidence of how these savings will be achieved. There is no full set of financial statements or granular revenue/cost data, making it difficult to independently verify the sustainability of the improvements or the sufficiency of the new capital. The claim that the new funds will bridge the company to profitability is not supported by cash flow projections or a reconciliation of funding needs versus expected burn. An independent analyst would conclude that while the top-line growth and narrowing losses are encouraging, the company remains loss-making, capital-intensive, and reliant on successful execution of both the asset sale and new product launches to justify its optimism.

Analysis

The announcement is upbeat, highlighting a proposed £5.5m placing, director participation, and a conditional £2m loan note, but much of the narrative is forward-looking and contingent. While Q1 FY26 revenue growth of ~60% is a realised fact, key benefits such as sustainable cash flow, profitability, and >£10m revenue from new products are projections, not current achievements. The sale of the CME stake is only at a non-binding stage, and the anticipated commercial launch of new products is not until 2027, indicating a long execution distance. The capital raise is significant, but immediate earnings impact is not expected; the company continues to incur losses and requires further funding. The language inflates the signal by framing intentions and beliefs as outcomes, with limited hard evidence for future profitability or product success. The data supports recent revenue growth and improved losses, but the majority of the upside is aspirational.

Risk flags

• ●Execution risk on asset sale: The agreement to sell the remaining 49% stake in Creo Medical Europe is non-binding, meaning there is no guarantee the transaction will complete. If the sale falls through, the company may not have sufficient cash to fund operations as planned.
• ●Reliance on future capital: The company’s own forecasts indicate that, without additional funding, it would exhaust its available cash resources and be unable to meet liabilities. This signals ongoing dependence on external capital markets, which may not always be accessible on favorable terms.
• ●Long-dated product pipeline: The anticipated commercial launch of the Bipolar product range is not until 2027, so any revenue or margin benefit is at least two years away. Investors face a long wait before seeing whether these products deliver the projected £10m+ revenue uplift.
• ●Lack of detailed financial disclosure: The announcement provides headline figures but omits a full set of financial statements, detailed cost breakdowns, or a clear use-of-proceeds schedule. This limits the ability to assess the true financial health and capital requirements.
• ●Persistent operating losses: Despite narrowing losses, the company reported a comprehensive loss of £17.5m in 2025 and expects further losses in the near term. This raises questions about the path to profitability and the risk of future dilutive fundraises.
• ●Forward-looking bias: The majority of the company’s claims are forward-looking, including revenue growth targets, cost reductions, and profitability timelines. These are not backed by binding contracts or detailed forecasts, increasing the risk that actual results will fall short.
• ●Geographic and operational complexity: The company operates across multiple jurisdictions (United States, Australia, Canada, Japan, South Africa, United Kingdom), which can introduce regulatory, operational, and execution risks, especially as it seeks to commercialize new products internationally.
• ●Insider participation caveat: While director participation in the placing is a positive signal of insider confidence, it does not guarantee future performance or institutional support. Investors should not conflate insider buying with a binding commitment to future funding or operational success.

Bottom line

For investors, this announcement means Creo Medical is raising significant new capital to fund ongoing operations, product development, and a potential asset sale, but the path to profitability remains unproven and distant. The company’s narrative is credible on recent revenue growth and improved losses, but the majority of the upside is based on projections, not realised results. Director participation in the placing is a mild positive, suggesting some insider confidence, but it does not guarantee future institutional support or operational success. The most material uncertainty is the non-binding nature of the CME stake sale; until this is executed and cash is received, the company’s funding position remains at risk. To change this assessment, the company would need to disclose binding agreements for the asset sale, detailed cash flow forecasts, and evidence of commercial traction for new products. Key metrics to watch in the next reporting period include actual completion of the CME stake sale, realised revenue growth (not just forecasts), cash burn rate, and any updates on product development timelines. Investors should treat this announcement as a signal to monitor rather than a call to action; the risk/reward profile is still highly speculative. The single most important takeaway is that while Creo Medical is making progress, its future depends on successful execution of several high-risk, long-dated initiatives that are far from guaranteed.

Announcement summary

Creo Medical Group plc (AIM:CREO) announced a proposed placing to raise approximately £5.5 million through the issue of about 36,666,664 new ordinary shares at 15 pence per share. Certain directors intend to subscribe for approximately £2.15 million in the placing. The company also announced a non-binding agreement for the potential sale of its remaining 49% stake in Creo Medical Europe, and a conditional subscription for £2 million of convertible loan notes by Development Bank of Wales. Year-on-year revenue growth for Q1 FY26 was approximately 60%, and the company expects full year FY26 revenue growth to be between 50% and 60% compared to FY25. The proceeds from the placing and loan notes will be used to support growth, commercial momentum, and working capital needs while mitigating completion risk of the CME Stake Disposal. The directors believe these actions will provide sufficient cash resources to fund development to sustainable cash flow generation and profitability. The company is targeting completion of the CME Stake Disposal within three months and anticipates the launch of new products in 2027.

Disagree with this article?